DCF — EPHRAIM MCDOWELL REG MED CTR
Enterprise Value: $-440.0M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-440.0M
Enterprise Value
$-137.1M
PV of Cash Flows
$-302.9M
PV of Terminal Value
$-487.8M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $213.9M | $-28.5M | -13.0% | $-37.6M | $-34.2M |
| Year 2 | $220.3M | $-27.2M | -12.0% | $-36.5M | $-30.2M |
| Year 3 | $227.0M | $-25.7M | -11.0% | $-35.3M | $-26.6M |
| Year 4 | $233.8M | $-25.3M | -11.0% | $-35.2M | $-24.1M |
| Year 5 | $240.8M | $-25.5M | -11.0% | $-35.7M | $-22.2M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-440.0M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$207.7M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.13840706285011126
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5